Enter DNA-damage gatekeeper WEE1. Targeting this kinase can prevent DNA repair in cancer cells and speed them towards their demise — which is what researchers at Debiopharm hope their ...

Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the ...

Improved safety window compared to single-target WEE1 inhibitors The Phase I clinical trial, set to launch in 2025, will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti ...

Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects Superior efficacy as a single agent and in combination therapies across various cancer models Preferential ...